ONO-4538 Phase II Rollover Study (ONO-4538-98)
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
Ono Pharmaceutical Co. Ltd
59 participants
Sep 10, 2020
INTERVENTIONAL
Conditions
Summary
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Eligibility
Inclusion Criteria2
- Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
- Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit
Exclusion Criteria2
- Participant judged to be incapable of providing consent for reasons such as concurrent dementia
- Participant judged by the investigator to be inappropriate as participants of this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV infusion over 30 minutes
IV infusion over 2 hours
Administered orally twice daily
Administered orally twice daily
IV infusion over 30 minutes
Administered orally once daily for 5 days every 28 days
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04566380